BioCentury | Oct 13, 2017
Emerging Company Profile

CBT’s silk road

While several Chinese biotechs have adopted a business model in which they in-license Western assets to develop for the China market, U.S.-based CBT Pharmaceuticals Inc. is doing the reverse, sourcing innovative Chinese assets to develop...
Items per page:
1 - 1 of 1